Abstract View

Author(s): Shivangi Yadav*1, Patel Dhara2, Patel Grishma3, Rashmi Rajeghorpade4, Dhananjay Meshram5

Email(s): 1yadavshivangi445@gmail.com

Address:

    Department of Pharmaceutical Quality Assurance, Pioneer Pharmacy College-390019,Gujarat India

Published In:   Volume - 5,      Issue - 6,     Year - 2026

DOI: https://doi.org/10.71431/IJRPAS.2026.5611  

 View HTML        View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
Pharmaceuticals have been credited with curing many diseases; however, there are unintentional exposures to toxins from drugs that have occurred at the manufacturing site, which can pose considerable risks to employees' health through unintentional contact. Thus, there is a need for us to protect workers from these dangers by limiting their level of exposure. This is done by defining the level of exposure that is acceptable or "occupational exposure limit" (OEL). OEL is the airborne concentration(s) over eight hours of work per day, for either a Working Lifetime). A definition of "acceptable daily exposure"(ADE) and "permitted daily exposure"(PDE) are established to define what is the maximum quantity of a pharmaceutical ingredient that may be present as a contaminant in another product, without it being harmful to the health of the end user. When adverse effects related to the exposure to an ingredient can be identified, the Point of Departure (Pod) that would be used in risk assessment is selected. Composite safety factors must be used in order to derive both ADE and PDE values. Each composite safety factor must include a variety of uncertainties identified at the time of establishment of the drug(s) being evaluated.

Cite this article:
Shivangi Yadav, Patel Dhara, Patel Grishma, Rashmi Rajeghorpade, Dhananjay Meshram. Optimizing OEL and ADE/PDE Compliance in Pharma. IJRPAS, June 2026; 5(6): 126-145.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2026.5611


References not available.

Related Images:



Recent Images



Assessing Philippine Health Care Coverage Gaps: An Assessment of Accessibility of Public Health Programs in Selected Barangay in Imus, Cavite, Philippines
Isoabsorptive UV Spectrophotometry Method development and validation for simultaneous estimation of Eslicarbazepine Acetate and Carbamazepine
To develop and validate the stability indicating method for repaglinide and voglibose using HPLC method
To develop and validate the stability indicating method for Empagliflozin and Linagliptin using HPLC method
A Prospective Observational Study on the Clinical Evaluation of Vertigoin Young Adult Population of Amaravati Capital Region
Quality by Design-Based Analytical Method Development and Validation of Suzetrigine by RP - HPLC
Formulation, Optimization and Evaluation of Rimegepant Pulsatile Tablets for Chronotherapeutic Management of Migraine
Development and Evaluation of Ticagrelor Solid Dispersion Tablets Using PVP K30, PEG 6000 and HPMC E5 for Dissolution Enhancement
To study the effect of various superdisintegrants and binders in the Formulation and Evaluation of Labetalol Rapid Disintegrating Tablet
To Develop and Validate the Stability Indicating Method for Ezetimibe and Rosuvastatin Using HPLC Method

Tags